Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting
03 Ottobre 2023 - 12:00PM
Business Wire
Studies highlight the clinical utility and
real-world impact of the Nodify CDT® and Nodify XL2® tests in
managing both benign and malignant pulmonary nodules.
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions
company with a focus in lung disease, today announced that new data
will be presented at the CHEST Annual Meeting 2023 in Honolulu,
Hawaiʻi. These presentations will provide new insight on the
clinical utility and real-world impact of the Nodify CDT and Nodify
XL2 tests in the comprehensive management of lung nodules.
The first abstract, titled "Real-World Impact of a
Blood-Based Integrated Classifier on the Management of Benign
Solid, Part-Solid, and Ground Glass Pulmonary Nodules," will be
presented by Jonathan Kurman, MD, Director of Interventional
Pulmonology at the Medical College of Wisconsin, on Tuesday,
October 10 at 12:00 pm HT (6:00 pm ET). The presentation will delve
into subgroup analyses from the prospective, real-world ORACLE
study (NCT03766958), evaluating the clinical utility of the Nodify
XL2 test across the spectrum of nodule types. The recently
published primary endpoint of the study highlighted a 74% reduction
in invasive procedures on benign nodules with use of the test. The
analysis will demonstrate that this reduction is consistent across
solid, part-solid, and ground glass lung nodules.
Dr. Kurman, remarked, "The data we're presenting at CHEST 2023
underscores the transformative potential of the Nodify XL2 test in
managing all types of lung nodules. Clinical guidelines recommend
different management strategies for solid versus non-solid nodules
and this data indicates the test can be used broadly to avoid
unnecessary invasive procedures."
The second abstract, titled "Comparison of a High Specificity
Blood-Based Biomarker with PET/CT for Identifying Malignant
Pulmonary Nodules," will be presented by Kathryn Long, MD,
Pulmonary and Critical Care Fellow at the Medical University of
South Carolina, on Wednesday, October 11 at 12:00 pm HT (6:00 pm
ET). The presentation will demonstrate the complementary nature of
the Nodify CDT test and PET/CT imaging results. PET/CT is a common
imaging technique that detects abnormal levels of cellular
metabolism and is clinically valuable in detecting cancer that has
spread throughout the body. However, published data shows that the
performance of PET/CT imaging alone is compromised in assessing
small lung nodules for cancer. The analysis will demonstrate that
the Nodify CDT test alongside PET/CT improves the performance,
identifying malignant nodules with a high level of accuracy.
Additionally, independent studies by external investigators are
expected at the event. "Novel Lung Cancer Biomarker Proteomic
Testing on Lung Nodule Risk Stratification and Clinical
Implications at a New York City Safety Net Hospital," is set to
be presented in a rapid-fire format by Dr. Sonu Sahni, MD on
Monday, October 9 at 12:00 pm HT (6:00 pm ET). Independent studies
underscore the growing utility and adoption of Nodify Lung testing
in the pulmonology community.
On Tuesday, October 10 at 1:00 pm HT (7:00 pm ET), Michael
Pritchett, DO, and Jonathan Kurman, MD, will discuss the
"Reduction of Diagnostic Interventions on Benign Lung Nodules:
Results from the Nodify XL2® Clinical Utility Study" at
Learning Theater 4. This presentation will highlight the ORACLE
study's findings, covering primary and exploratory endpoints as
well as multiple subgroup analyses from the study that have been
published to date.
About Biodesix Biodesix is a leading diagnostic solutions
company with a focus in lung disease. The Company develops
diagnostic tests addressing important clinical questions by
combining multi-omics through the power of artificial intelligence.
Biodesix offers five Medicare-covered tests for patients with lung
diseases. The blood based Nodify Lung® nodule risk assessment
testing strategy, consisting of the Nodify XL2® and the Nodify CDT®
tests, evaluates the risk of malignancy in pulmonary nodules,
enabling physicians to better triage patients to the most
appropriate course of action. The blood based IQLung™ strategy for
lung cancer patients integrates the GeneStrat® targeted ddPCR™
test, the GeneStrat NGS™ test and the VeriStrat® test to support
treatment decisions across all stages of lung cancer with results
in an average of two to three business days, expediting the time to
treatment. Biodesix also leverages the proprietary and advanced
Diagnostic Cortex® AI (Artificial Intelligence) platform, to
collaborate with many of the world’s leading biotechnology and
pharmaceutical companies to solve complex diagnostic challenges in
lung disease. For more information about Biodesix, visit
biodesix.com.
Note Regarding Forward-Looking Statements This press
release may contain forward-looking statements that involve
substantial risks and uncertainties for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release other than
statements of historical fact, are forward-looking statements. The
words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, its possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. The Company's ability to continue as a
going concern could cause actual results to differ materially from
those contemplated in this press release and additionally, other
factors that could cause actual results to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Biodesix’s most recent annual report on Form
10-K, filed March 14, 2022 or subsequent quarterly reports on Form
10-Q during 2022, if applicable. Biodesix undertakes no obligation
to revise or publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20230712545799/en/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231003224718/en/
Media: Robbie Lunt robbie.lunt@biodesix.com
1-866-432-5930
Investors: Chris Brinzey chris.brinzey@westwicke.com
(339) 970-2843
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Biodesix (NASDAQ:BDSX)
Storico
Da Set 2023 a Set 2024